Elisa de Carvalho
Research Subjects
Elisa de Carvalho has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Gilda Porta
Hepatology and Liver Transplantation Hospital Sírio‐Libanês and Hospital Samaritano São Paulo Brazil
5 shared publications - Cibele Dantas Ferreira Marques
Faculdade de Medicina da Universidade Federal da Bahia (UFBA), Salvador, BA, Braziç
4 shared publications - Cristina Targa Ferreira
Hospital da Criança Santo Antônio
4 shared publications - Irene Kazue Miura
Hepatology and Liver Transplantation Hospital Sírio‐Libanês and Hospital Samaritano São Paulo Brazil
4 shared publications - Maria Angela Bellomo-Brandão
Universidade Estadual de Campinas, Brazil
4 shared publications - Regina Sawamura
Universidade de São Paulo (USP), Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto (FMRP), Departamento de Puericultura e Pediatria, Ribeirão Preto, SP, Brazil
4 shared publications
Latest Publications
- Open Access
- 29 October 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 103 (1)
Eosinophilic esophagitis in pediatrics: advances in diagnosis, treatment, and follow-up
- 29 October 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 103 (1)
Open AccessEosinophilic esophagitis in pediatrics: advances in diagnosis, treatment, and follow-up
- Open Access
- 31 July 2026
- Published by Wiley in JPGN Reports
The Brazilian Alagille syndrome study: New insights from a multicenter national cohort
Objectives: To elucidate the natural history of liver disease and identify the predictors of native liver survival (NLS) in a Brazilian cohort of children with Alagille syndrome (ALGS). Methods: Multicenter retrospective cohort study of children with ALGS. Descriptive statistics summarized clinical data. Overall survival was estimated using Kaplan–Meier curves. NLS was analyzed with competing risk models. Associations between laboratory parameters and NLS were tested using Pearson′s chi‐square. Results: From 14 Brazilian reference centers, 120 children (52.5% male) were included, with mean age at diagnosis of 17.8 months and a median follow‐up time of 88.5 months. Most presented characteristic facies (89.9%), jaundice (88.2%), pruritus (87.9%), and neonatal cholestasis (79.2%). Thirty percent underwent liver transplantation (LT) and 6.7% died. Jaundice, xanthomas, hepatomegaly, splenomegaly, and presence of excoriations were significantly associated with the need for LT or death. Direct bilirubin (DB) > 6 mg/dL, cholesterol >300 mg/dL, increased aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN), and AST‐to‐platelet ratio index (APRI) > 1 were associated with a significantly increased risk of LT or death, with hazard ratios of 18.2 ( p < 0.001, 95% confidence interval [95% CI] = 5.1–64.5), 3.4 ( p = 0.016, 95% CI = 1.3–9.2), 3.9 ( p = 0.018, 95% CI = 1.2–12.4), and 10.2 ( p = 0.013, 95% CI = 1.3–82.2), respectively. Conclusions: The main clinical manifestations included characteristic facies, jaundice, and pruritus. Higher rates of LT or death were associated with jaundice, xanthomas, hepatomegaly, splenomegaly and presence of excoriations. Higher rates of NLS were associated with DB levels below 6 mg/dL, cholesterol levels below 300 mg/dL, AST levels <5x ULN, and an APRI < 1.
- 31 July 2026
- Published by Wiley in JPGN Reports
Open AccessThe Brazilian Alagille syndrome study: New insights from a multicenter national cohort
Objectives: To elucidate the natural history of liver disease and identify the predictors of native liver survival (NLS) in a Brazilian cohort of children with Alagille syndrome (ALGS). Methods: Multicenter retrospective cohort study of children with ALGS. Descriptive statistics summarized clinical data. Overall survival was estimated using Kaplan–Meier curves. NLS was analyzed with competing risk models. Associations between laboratory parameters and NLS were tested using Pearson′s chi‐square. Results: From 14 Brazilian reference centers, 120 children (52.5% male) were included, with mean age at diagnosis of 17.8 months and a median follow‐up time of 88.5 months. Most presented characteristic facies (89.9%), jaundice (88.2%), pruritus (87.9%), and neonatal cholestasis (79.2%). Thirty percent underwent liver transplantation (LT) and 6.7% died. Jaundice, xanthomas, hepatomegaly, splenomegaly, and presence of excoriations were significantly associated with the need for LT or death. Direct bilirubin (DB) > 6 mg/dL, cholesterol >300 mg/dL, increased aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN), and AST‐to‐platelet ratio index (APRI) > 1 were associated with a significantly increased risk of LT or death, with hazard ratios of 18.2 ( p < 0.001, 95% confidence interval [95% CI] = 5.1–64.5), 3.4 ( p = 0.016, 95% CI = 1.3–9.2), 3.9 ( p = 0.018, 95% CI = 1.2–12.4), and 10.2 ( p = 0.013, 95% CI = 1.3–82.2), respectively. Conclusions: The main clinical manifestations included characteristic facies, jaundice, and pruritus. Higher rates of LT or death were associated with jaundice, xanthomas, hepatomegaly, splenomegaly and presence of excoriations. Higher rates of NLS were associated with DB levels below 6 mg/dL, cholesterol levels below 300 mg/dL, AST levels <5x ULN, and an APRI < 1.
- Open Access
- 10 March 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (3) , 101522
Biliary Atresia: advances and challenges in early diagnosis and management
- 10 March 2026
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (3) , 101522
Open AccessBiliary Atresia: advances and challenges in early diagnosis and management
- Open Access
- 9 March 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (7) , 1591-1600
Hepatic Glycogen Storage Diseases in Brazil: A Multicenter Study
To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (12 IIIa, 1 IIIb), 1 (0.8%) type IV, 6 (4.5%) type VI, and 49 (37.1%) with type IX (28 IXa, 7 IXb, and 14 IXc). Type I patients presented earlier (4 months) and had more episodes of hypoglycemia at clinical presentation ( p < 0.001). Anthropometric data at admission revealed impaired growth, with a tendency toward short stature across the groups (median −2.06, −1.89, and −1.96 among type I, III, and IX respectively). The median body mass index (BMI) z ‐scores at admission for all three types were above +1. Only patients with type IX demonstrated significant improvement in height ( p = 0.007) and BMI ( p = 0.020) z ‐scores during follow‐up. Regarding laboratory tests, significant decreases were observed in total cholesterol, triglycerides, venous lactate and aminotransferases in patients with types I and IX. Hepatic GSDs are heterogeneous diseases. There is a significant height impairment with a troublesome trend to overweight and obesity, especially in type I. Although there is improvement in aminotransferases, cholesterol, and triglycerides with follow‐up, adherence to treatment remains a challenge.
- 9 March 2026
- Published by Wiley in American Journal of Medical Genetics Part A
- Vol. 200 (7) , 1591-1600
Open AccessHepatic Glycogen Storage Diseases in Brazil: A Multicenter Study
To describe clinical and laboratory characteristics, emphasizing the evolution of patients with hepatic glycogen storage diseases (GSDs) followed in Brazilian reference centers. Multicenter, retrospective study involving 13 centers, using RedCap platform. 132 patients were included: 63 (47.8%) GSD type I (56 Ia, 7 Ib), 13 (9.8%) with type III (12 IIIa, 1 IIIb), 1 (0.8%) type IV, 6 (4.5%) type VI, and 49 (37.1%) with type IX (28 IXa, 7 IXb, and 14 IXc). Type I patients presented earlier (4 months) and had more episodes of hypoglycemia at clinical presentation ( p < 0.001). Anthropometric data at admission revealed impaired growth, with a tendency toward short stature across the groups (median −2.06, −1.89, and −1.96 among type I, III, and IX respectively). The median body mass index (BMI) z ‐scores at admission for all three types were above +1. Only patients with type IX demonstrated significant improvement in height ( p = 0.007) and BMI ( p = 0.020) z ‐scores during follow‐up. Regarding laboratory tests, significant decreases were observed in total cholesterol, triglycerides, venous lactate and aminotransferases in patients with types I and IX. Hepatic GSDs are heterogeneous diseases. There is a significant height impairment with a troublesome trend to overweight and obesity, especially in type I. Although there is improvement in aminotransferases, cholesterol, and triglycerides with follow‐up, adherence to treatment remains a challenge.
- Open Access
- 2 November 2022
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 25 (6) , 489-499
Pediatric Liver Transplantation: Caregivers’ Quality of Life
Bastos Tavares AP, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Nov;25(6):489-499. https://doi.org/10.5223/pghn.2022.25.6.489
- 2 November 2022
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 25 (6) , 489-499
Open AccessPediatric Liver Transplantation: Caregivers’ Quality of Life
Bastos Tavares AP, et al. Pediatr Gastroenterol Hepatol Nutr. 2022 Nov;25(6):489-499. https://doi.org/10.5223/pghn.2022.25.6.489
- Open Access
- 1 January 2020
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 23 (3) , 286-296
Quality of Life in Children and Adolescents with Inflammatory Bowel Disease: Impact and Predictive Factors
Silva LC, et al. Pediatr Gastroenterol Hepatol Nutr. 2020 May;23(3):286-296. https://doi.org/10.5223/pghn.2020.23.3.286
- 1 January 2020
- Published by XMLink in Pediatric Gastroenterology, Hepatology & Nutrition
- Vol. 23 (3) , 286-296
Open AccessQuality of Life in Children and Adolescents with Inflammatory Bowel Disease: Impact and Predictive Factors
Silva LC, et al. Pediatr Gastroenterol Hepatol Nutr. 2020 May;23(3):286-296. https://doi.org/10.5223/pghn.2020.23.3.286
- Open Access
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 95 (4) , 419-427
Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria (Versão em Português)
- Vol. 95 (4) , 419-427
Open AccessAutoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes
- Open Access
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria
- Vol. 95 (4) , 419-427
Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes
- 1 July 2019
- Published by Elsevier in Jornal de Pediatria
- Vol. 95 (4) , 419-427
Open AccessAutoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes